Sulfatide inhibits HIV-1 entry into CD4-/CXCR4+ cells

Virology

Volumn 246, Issue 2, 1998, Pages 211-220

  Fantini, Jacques ^a   HamMacHe, Djilali ^a   Delézay, Olivier ^a   Piéroni, Gérard ^c   Tamalet, Catherine ^c   Yahi, Nouara ^b  

^a Facultedes Sci St Jerome   (France)

^b TIMONE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

CD4; Coreceptor; CXCR4; GalCer; Glycolipids; HIV 1 infection

Indexed keywords

GLYCOPROTEIN GP 120; SULFATIDE;

ARTICLE; CONTROLLED STUDY; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS;

AMPHOTROPIC MURINE LEUKEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; RNA VIRUSES;

EID: 0032486591     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9216     Document Type: Article

References (50)

1. Albright A. V., Lavi E., O'Connor M., Gonzalez-Scarano F. HIV-1 infection of a CD4-negative primary cell type: The oligodendrocyte. Perspect. Drug Discov. Des. 5:1996;43-50.
2. Alkhatib G., Combadiere C., Broder C. C., Feng Y., Kennedy P. E., Murphy P. M., Berger E. A. CC CKR5: A RANTES, MIP1α, MIP1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
3. Barré-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Axler-Blin C., Brun-Vezinet F., Rouzioux C., Rozenbaum W., Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome. Science. 220:1983;868-870.
4. Basgara O., Lavi E., Bobroski L., Khalili K., Pestaner J. P., Pomerantz R. Cellular reservoirs of HIV-1 in the central nervous system of infected-individuals: Identification by combination of in situ PCR and immunohistochemistry. AIDS. 10:1996;573-585.
5. Berger E. A., Doms R. W., Fenyö E. M., Korber B. T. M., Littman D. R., Moore J. P., Sattentau Q. J., Schuitemaker H., Sodroski J., Weiss R. A. A new classification for HIV-1. Nature. 391:1998;240.
6. Berson J. F., Long D., Doranz B. J., Rucker J., Jirik F. R., Doms R. W. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1. J. Virol. 70:1996a;6288-6295.
7. Berson J. F., Doms R. W., Long D. Interaction of human immunodeficiency virus type 1 envelope protein with liposomes contaning galactosylceramide. Perspect. Drug Discov. Des. 5:1996b;169-180.
8. Bhat S., Spitalnik S. L., Gonzalez-Scarano F., Silberberg D. H. Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 88:1991;7131-7134.
9. Bhat S., Mettus R. V., Reddy E. P., Ugen K. E., Srikanthan V., Williams W. V., Weiner D. B. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275. AIDS Res. Hum. Retroviruses. 9:1993;175-181.
10. Brogi A., Presentini R., Solazzo D., Piomboni B., Costantino-Ceccarini E. Interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with a galactoglycerolipid associated with human sperm. AIDS Res. Hum. Retroviruses. 12:1996;483-489.
11. Brossmer R., Isecke R., Herrler G. A sialic acid analogue acting as a receptor determinant for binding but not for infection by influenza C virus. FEBS Lett. 323:1993;96-98.
12. Callies R., Schwarzmann G., Radsak K., Siegert R., Wiegandt H. Characterization of the cellular binding of exogenous gangliosides. Eur. J. Biochem. 80:1977;425-432.
13. Collman R., Balliet J. W., Gregory S. A., Friedman H., Kolson D. L., Nathanson N., Srinivasan A. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of the human immunodeficiency virus type 1. J. Virol. 66:1992;7517-7521.
14. Cook D. G., Fantini J., Spitalnik S. L., Gonzalez-Scarano F. Binding of human immunodeficiency virus type 1 (HIV-1) gp120 to galactosylceramide (GalCer): Relationship to the V3 loop. Virology. 201:1994;206-214.
15. Dean G. A., Reubel G. H., Pedersen N. C. Simian immunodeficiency virus infection of CD8+ lymphocytes in vivo. J. Virol. 70:1996;5646-5650.
16. Delézay O., Yahi N., Tamalet C., Baghdiguian S., Boudier J. A., Fantini J. Direct effect of type 1 human immunodeficiency virus (HIV-1) on intestinal epithelial cell differentiation: Relationship to HIV-1 enteropathy. Virology. 238:1997a;231-242.
17. Delézay O., Koch N., Yahi N., Hammache D., Tourres C., Tamalet C., Fantini J. Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29. AIDS. 11:1997b;1311-1318.
18. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R. E., Hill C. M., Davis C. B., Peiper S. C., Schall T. J., Littman D. R., Landau N. R. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
19. Doranz B. J., Rucker J., Yi Y., Smyth R. J., Samson M., Peiper S. C., Parmentier M., Collman R. G., Doms R. W. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 85:1996;1149-1158.
20. Dragic T., Litwin V., Allaway G. P., Martin S. R., Huang Y., Nagashima K. A., Cayanan C., Maddon P., Koup R. A., Moore J. P., Paxton W. A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
21. Ellrodt A., Barré-Sinoussi F., Le Bras F., Nugeyre M. T., Palazzo L., Rey F., Brun-Vezinet F., Rouzioux C., Segond P., Caquet R., Montagnier L., Chermann J. C. Isolation of a new human T-lymphotropic retrovirus (LAV) from a married couple of Zairians, one with AIDS, the other with prodromes. Lancet. 1:1984;1383-1385.
22. Endres M. J., Clapham P. R., Marsh M., Ahuja M., Davis Turner J., McKnight A., Thomas J. F., Stoebenau-Haggarty B., Choe S., Vance P. J., Wells T. N. C., Power C. A., Sutterwala S. S., Doms R. W., Landau N. R., Hoxie J. A. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell. 87:1996;745-756.
23. Fantini J., Cook D. G., Nathanson N., Spitalnik S. L., Gonzalez-Scarano F. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus (HIV-1) is associated with cell surface expression of galactosyl ceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. USA. 90:1993;2700-2704.
24. Fantini J., Yahi N., Delezay O., Gonzalez-SCarano F. GalCer, CD26 and HIV infection of intestinal epithelial cells. AIDS. 8:1994;1347-1348.
25. Fantini J., Hammache D., Delézay O., Yahi N., André-Barrès C., Rico-Lattes I., Lattes A. Synthetic soluble analogs of galactosylceramide (Galcer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry. J. Biol. Chem. 272:1997;7245-7252.
26. Feng Y., Broder C. C., Kenedy P. E., Berger E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 272:1996;872-877.
27. Furuta Y., Eriksson K., Svennerholm B., Fredman P., Horal P., Jeansson S., Vahlne A., Holmgren J., Czerkinsky C. infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 91:1994;12559-12563.
28. Harouse J. M., Kunsch C., Hartle H. T., Laughlin M. A., Hoxie J. A., Wigdahl B., Gonzalez-Scarano F. CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J. Virol. 63:1989;2527-2533.
29. Harouse J. M., Bhat S., Spitalnik S. L., Laughlin M., Stefano K., Silberberg D. H., Gonzalez-Scarano F. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science. 253:1991;320-323.
30. Harouse J. M., Collman R., Gonzalez-Scarano F. Human immunodeficiency virus type 1 infection of SK-N-MC cells: Domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3′ sulfo-galactosyl ceramide-positive cell line. J. Virol. 69:1995;7383-7390.
31. Haywood A. M. Virus receptors: Binding, adhesion strenghtening, and changes in viral structure. J. Virol. 68:1994;1-5.
32. Haywood A. M., Boyer B. P. Sendai virus membrane fusion: Time course and effect of temperature, pH, calcium, and receptor concentration. Biochemistry. 21:1982;6041-6046.
33. Hill C. M., Deng H., Unumatz D., Kewalramani V. N., Bastiani L., Gorny M. K., Zolla-Pazner S., Littman D. R. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J. Virol. 71:1997;6296-6304.
34. Kimura-Kuroda J., Nagashima K., Yasui K. Inhibitory effects of HIV-1 gp120 on myelin formation. Perspect. Drug Discov. Des. 5:1996;17-29.
35. Lapham C. L., Ouyang J., Chandrasekhar B., Nguyen N. Y., Dimitrov D. S., Golding H. Evidence for cell surface association between fusin and the CD4-gp120 complex in human cell lines. Science. 274:1996;602-605.
36. Lear J. D., Rafalski M. Peptide-bilayer interactions: physical measurements related to peptide structure. Viral Fusion Mechanisms. 1993;CRC Press, Boca Raton. p. 55-66.
37. Livingstone W. J., Moore M., Innes D., Whitelaw J., Wyld R., Robertson J. R., Brettle R. P., Bell J. E., Simmonds P. Frequent infection of CD8 lymphocytes by HIV-1 in peripheral blood of AIDS patients. Lancet. 348:1996;649-654.
38. Long D., Berson J. F., Cook D. G., Doms R. W. Characterization of human immunodeficiency virus type 1 gp120 binding to liposomes containing galactosylceramide. J. Virol. 68:1994;5890-5898.
39. Maggio B. The surface behavior of glycosphingolipids in biomembranes: A new frontier of molecular ecology. Prog. Biophys. Mol. Biol. 62:1996;55-117.
40. McAlarney T., Apostolski S., Lederman S., Latov N. Characteristics of HIV-1 gp120 glycoprotein binding to glycolipids. J. Neurosci. Res. 37:1994;453-460.
41. Rantsch B., Clapshaw P. A., Price J., Noble M., Seifert W. Development of oligodendrocyte and Schwann cells studied with a monoclonal antibody against galactocerebroside. Proc. Natl. Acad. Sci. USA. 79:1982;2936-2939.
42. Speck R. E., Wehrly K., Platt E. J., Atchison R. E., Charo I. F., Kabat D., Chesebro B., Goldsmith M. A. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J. Virol. 71:1997;7136-7139.
43. Tateno M., Gonzalez-Scarano F., Levy J. A. Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc. Natl. Acad. Sci. USA. 86:1989;4287-4290.
44. Trujillo J. R., Wank W. K., Lee T. H., Essex M. Identification of the envelope V3 loop as a determinant of a CD-negative neuronal cell tropism for HIV-1. Virology. 217:1996;613-617.
45. Wu L., Gerard N. P., Wyatt R. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384:1996;179-183.
46. Yahi N., Baghdiguian S., Moreau H., Fantini J. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT-29 cells. J. Virol. 66:1992;4848-4854.
47. Yahi N., Sabatier J. M., Nickel P., Mabrouk K., Gonzalez-Scarano F., Fantini J. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J. Biol. Chem. 269:1994a;24349-24353.
48. Yahi N., Spitalnik S. L., Stefano K. A., De Micco P., Gonzalez-Scarano F., Fantini F. Interferon-γ decreases cell surface expression of galactosylceramide, the receptor for HIV-1 gp120 on human colonic epithelial cells. Virology. 204:1994b;550-557.
49. Yahi N., Sabatier J. M., Baghdiguian S., Gonzalez-Scarano F., Fantini J. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line. J. Virol. 69:1995;320-325.
50. -+. Perspect. Drug Discov. Des. 5:1996;161-168.